https://scholars.lib.ntu.edu.tw/handle/123456789/503491
標題: | Long-term durability of responses to 2 or 3 doses of hepatitis a vaccination in human immunodeficiency virus-positive adults on antiretroviral therapy | 作者: | ARISTINE CHENG SUI-YUAN CHANG HSIN-YUN SUN Tsai M.-S. Liu W.-C. Su Y.-C. Wu P.-Y. CHIEN-CHING HUNG SHAN-CHWEN CHANG |
公開日期: | 2017 | 卷: | 215 | 期: | 4 | 起(迄)頁: | 606-613 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. Previous studies have shown that the durability of serological response is impaired in successfully vaccinated human immunodeficiency virus1 (HIV-1) positive subjects after receiving 2 doses of inactivated hepatitis A virus (HAV) vaccine. We evaluated whether 3 doses compared with 2 doses of HAV vaccine could improve the long-term seroprotection for this susceptible group. Methods. Antibody persistence among HIV-positive men who have sex with men aged 1840 years who had received 2 or 3 doses of HAV vaccine according to a 06- or a 016-month schedule was evaluated biannually for 5 consecutive years in this prospective, nonrandomized cohort study. Results. At the end of 5 years, seroprotection persisted in 79% (146/185) versus 76% (85/110) and 94% (146/155) versus 88% (84/95) of the 3- versus 2-dose primary responders by intention-to-treat and per-protocol analyses, respectively (P ? .05). Throughout the 5 years, the geometric mean concentrations of anti-HAV immunoglobulin G (IgG) were significantly higher for the 3-dose than the 2-dose group. In the multivariable analysis, a 3-dose regimen compared with a 2-dose regimen (odds ratio = 3.36; 95% confidence interval = 1.149.93) was independently associated with sustained seroprotection. Conclusions. Three doses versus 2 doses of HAV vaccine improve the durability of immune responses in terms of higher concentrations of specific IgG, which take longer to decay to subthreshold levels. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/503491 | ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jiw605 | SDG/關鍵字: | antiretrovirus agent; bilirubin; hepatitis A vaccine; immunoglobulin G antibody; antiretrovirus agent; hepatitis A antibody; hepatitis A vaccine; immunoglobulin G; inactivated vaccine; virus RNA; adult; antibody titer; antiretroviral therapy; Article; bilirubin blood level; CD4 lymphocyte count; cohort analysis; controlled clinical trial; controlled study; disease association; drug efficacy; hepatitis A; high risk behavior; human; Human immunodeficiency virus; Human immunodeficiency virus infection; incidence; intention to treat analysis; major clinical study; male; men who have sex with men; prospective study; seroconversion; treatment response; virus load; adolescent; blood; dose response; follow up; hepatitis A; HIV Infections; immunology; isolation and purification; longitudinal study; multivariate analysis; secondary immunization; time factor; vaccination; young adult; Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Immunologic; Follow-Up Studies; Hepatitis A; Hepatitis A Antibodies; Hepatitis A Vaccines; HIV Infections; Humans; Immunization, Secondary; Immunoglobulin G; Longitudinal Studies; Male; Multivariate Analysis; Prospective Studies; RNA, Viral; Time Factors; Vaccination; Vaccines, Inactivated; Viral Load; Young Adult |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。